Clinical Edge Journal Scan

Shorter-duration trastuzumab noninferior in early breast cancer


 

Key clinical point : For patients with early breast cancer, ≤ 6 months of adjuvant trastuzumab was noninferior to a 1-year course and appeared to be less cardiotoxic.

Major finding: 5-year DFS rates were 85.4% vs. 87.1%, respectively. Rates of congestive heart failure were 3.9% vs. 6.9%, respectively.

Study details : Meta-analysis of 5 randomized trials (11,376 patients).

Disclosures: Funding sources were not reported. Two coinvestigators disclosed ties to Roche, Eisai, Novartis, Sanofi, Kendle India, and several other pharmaceutical companies.

Citation: Gulia S et al. 2020 Aug 24. JAMA Netw Open . doi: 10.1001/jamanetworkopen.2020.11777

Recommended Reading

Chronicles of Cancer: A history of mammography, part 2
MDedge Hematology and Oncology
Hair dye and cancer study ‘offers some reassurance’
MDedge Hematology and Oncology
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results
MDedge Hematology and Oncology
Study supports multigene panel testing for all breast cancer patients with second primary cancers
MDedge Hematology and Oncology
AI algorithm on par with radiologists as mammogram reader
MDedge Hematology and Oncology
Survey quantifies COVID-19’s impact on oncology
MDedge Hematology and Oncology
System provides ‘faster, less invasive’ method for breast cancer detection
MDedge Hematology and Oncology
Postmenopausal use of estrogen alone lowers breast cancer cases, deaths
MDedge Hematology and Oncology
Study eyes breast cancer mortality in older women
MDedge Hematology and Oncology
Checkpoint inhibitors of limited benefit in metastatic breast cancer
MDedge Hematology and Oncology